Was reassuring last night to hear how early this particular research still is. It is easy to get stuck in the echo chamber we call twitter and feel like you are constantly behind, but some of the non-crypto / non-twitter natives who are well versed in the field were not even aware of the possibilities that open up with peptides. I got along well with a very talented woman who's main focus at the moment happened to be on the TAU protein (one of the many that @clarity_proto studies that is associated with neurodegenerative disease) and she had no idea peptides were even capable of crossing the blood-brain barrier. There is plenty of room to grow.
Each peptide has an expected range of effects, but outcomes vary by individual.
What works for one person, at one dose, in one context, may not translate the same way to another. That gap between published evidence and real world results is where most decisions break down.
Peptome fills that gap with an evidence driven layer that surfaces what's more likely to work for you, based on similar profiles and real world data.
It doesn't just aggregate research, it grades it, contextualizes it, and connects it to actual outcomes over time. Every protocol, every log, every result feeds back into the system.
A closed loop between what's known and what actually works.
#longevity
Dex got updated fees got properly sent to @midware_midwife and we sitting at 20k?
We either fix up and build a community or go back to getting rugged chasing shitters
This is TEK you don’t swing these kinda plays you HODL and wait
$Wormtower 👀🪱
🧬 TrackedBio is heading to SynBioBeta 2026.
May 4–7 · San Jose Convention Center · Booth 211
We'll be doing a live demonstration our flagship products, which facilities are using to accelerate their phenomics pipelines.
Need to fix the replication crisis in science.
Crowd sourced voting on which papers to test and prediction markets on what will replicate offers a potential path.